Trade Mark Journal No.2026/037 11 September 2026
UK00004437444 28 August 2026 (5,42,44)
KUVOVDA
International priority date claimed: 12 August 2026
(United States of America)
(50045963)
- Class 5
- Pharmaceuticals; pharmaceutical preparations; pharmaceutical products; biologics; biosimilars; pegfilgrastim biosimilars; pharmaceutical preparations for the treatment of neutropenia; pharmaceutical preparations for the treatment of low white blood cells; pharmaceutical preparations for use in stimulating white blood cell production; biosimilars for use in stimulating white blood cell production; pharmaceutical preparations, namely, recombinant-human granulocyte-CSF for use in stimulating white blood cell production; recombinant-human granulocyte-CSF biosimilars for use in stimulating white blood cell production; pharmaceutical preparations, namely, injectable pegfilgrastim biosimilars; pharmaceutical preparations, namely, injectable biosimilars for the treatment of neutropenia; pharmaceutical preparations, namely, injectable biosimilars for the treatment of low white blood cells; pharmaceutical preparations, namely, injectable biosimilars for use in stimulating white blood cell production; pharmaceutical preparations, namely, injectable recombinant-human granulocyte-CSF for use in stimulating white blood cell production; pharmaceutical preparations, namely, injectable recombinant-human granulocyte-CSF biosimilars for use in stimulating white blood cell production; injectors sold filled with pegfilgrastim biosimilars; injectors sold filled with pharmaceutical preparations for the treatment of neutropenia; injectors sold filled with pharmaceutical preparations for the treatment of low white blood cells; injectors sold filled with pharmaceutical preparations for use in stimulating white blood cell production; injectors sold filled with biosimilars for use in stimulating white blood cell production; injectors sold filled with recombinant-human granulocyte-CSF for use in stimulating white blood cell production; injectors sold filled with recombinant-human granulocyte-CSF biosimilars for use in stimulating white blood cell production.
- Class 42
- Providing information in the field of scientific and medical research related to pharmaceuticals; providing information in the field of scientific and medical research related to cancer and cancer treatments; research and development of pharmaceuticals; research and development of pharmaceuticals in the field of cancer and cancer treatments.
- Class 44
- Providing medical information; providing health information; providing medical information in the field of cancer and cancer treatments; providing health information in the field of cancer and cancer treatments; medical and pharmaceutical consultation; pharmaceutical advice; providing information to patients in the field of administering medications; individual medical counseling services provided to patients; providing personal support services for families of patients with life threatening disorders, namely, health counseling services.
Hong Kong King-Friend, Industrial Company, Ltd.
Representative: Bryers Intellectual Property Ltd